Leading Republicans in the House of Representatives have formally introduced their latest version of the bill to establish a regulatory structure for digital assets markets, something the industry ...

The FDA is set to decide by June 10, 2025, on Merck's Clesrovimab, a long-acting monoclonal antibody developed to protect infants from respiratory syncytial virus (RSV) during their first RSV season.

Despite these differences, your organizational structure has to satisfy basic manufacturing requirements and fulfill common operational functions. Once you have set up your organization to meet ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. A lot of organizations like to say publicly that “the client comes first.” ...

A research team led by Dr. Weizheng Fu and Professor Yuichi Otsuka from Nagoya University's Institute for Space-Earth Environmental Research (ISEE) has captured the detailed 3D structure of ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

Since small businesses can't change the structure of the market, you have to analyze how it affects your firm, identify the negative aspects and change your company's approach to the market to ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

A regulatory application seeking approval for clesrovimab, its respiratory syncytial virus vaccine, is under review in the United States, with an FDA decision expected in June. To foray into the ...

with results showing Beyfortus prevents more medically attended RSV cases when compared with clesrovimab, another antibody in development. Beyfortus has amassed real-world data in over 40 studies ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...